McKesson (MCK)
(Delayed Data from NYSE)
$589.95 USD
-1.12 (-0.19%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $590.00 +0.05 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$589.95 USD
-1.12 (-0.19%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $590.00 +0.05 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Zacks News
Will Core Distribution Unit Aid McKesson (MCK) Q1 Earnings?
by Zacks Equity Research
Strong prospects in the Distribution Solutions segment is likely to boost McKesson's (MCK) top-line performance in the fiscal first quarter.
Will Core Segmental Growth Aid Stryker (SYK) in Q2 Earnings?
by Zacks Equity Research
Stryker's (SYK) strong segmental performance and acquisition-driven strategy are likely to drive Q2 earnings.
Should Value Investors Consider McKesson (MCK) Stock Now?
by Zacks Equity Research
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Amazon Forays Into Pharmacy Business: Red Alert for Others?
by Sweta Jaiswal
Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.
McKesson (MCK) Issues Strong Preliminary Results for Q1
by Zacks Equity Research
McKesson Corporation (MCK) declares solid preliminary results for Q1, courtesy of deals, divestitures and acquisitions.
Why Is McKesson (MCK) Up 1.7% Since Its Last Earnings Report?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson's (MCK) Q4 Earnings Miss Estimates, Sales Improve Y/Y
by Zacks Equity Research
McKesson (MCK) witnesses strong growth in its Distribution Solutions segment in Q4 of fiscal 2018.
Is McKesson Corporation (MCK) a Suitable Value Stock Now?
by Zacks Equity Research
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Top Stock Reports for Lockheed Martin, Mastercard & Colgate
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Lockheed Martin (LMT), Mastercard (MA) and Colgate (CL).
McKesson (MCK) Beats on Earnings and Sales in Q3
by Zacks Equity Research
McKesson Corporation (MCK) delivers strong performance on the back of solid organic growth.
McKesson (MCK) Beats on Earnings and Sales in Q2
by Zacks Equity Research
McKesson's adjusted earnings of $3.28 per share came above the Zacks Consensus Estimate of $2.78 and increased from $2.96 in the year-ago quarter.
Should You Buy McKesson Corporation (MCK) Ahead of Earnings?
by Zacks Equity Research
McKesson (MCK) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Mckesson (MCK) to Report Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
McKesson Corporation (MCK) expects a strong second quarter owing to a gradually stabilizing generic and branded market.
Is McKesson (MCK) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now from multiple angles.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) is facing immediate integration risks from its acquisition of PharMEDium. Also, competition in the generic space raise concern.
McKesson (MCK) Misses on Earnings and Sales in Q1
by Zacks Equity Research
McKesson???s adjusted earnings of $2.46 per share missed the Zacks Consensus Estimate of $2.81 and decreased from $3.15 in the year-ago quarter.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
On Jul 10, we issued an updated research report on Chesterbrook, PA-based AmerisourceBergen Corporation (ABC).
Should Value Investors Consider McKesson (MCK) Stock?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Why Is McKesson (MCK) Up 13% Since the Last Earnings Report?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson (MCK) Up 7.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson Corporation: Should Value Investors Pick this Stock?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
McKesson (MCK) Beats on Earnings in Q3, Inks Buyout Deal
by Zacks Equity Research
McKesson Corporation (MCK) reported third-quarter fiscal 2017 earnings of $3.03 per share, beating the Zacks Consensus Estimate of $2.95 but declining from the year-ago figure of $3.18.
McKesson (MCK) Q3 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
McKesson Corporation (MCK), one of the largest healthcare services providers, is scheduled to report third-quarter fiscal 2017 results on Jan 25.
McKesson (MCK) to Pay $150 Million to Department of Justice
by Zacks Equity Research
McKesson (MCK) has finalized to resolve U.S. Drug Enforcement Administration and Department of Justice potential federal civil and administrative claims.
McKesson (MCK) Closes Rexall Health Acquisition in Canada
by Zacks Equity Research
McKesson Corporation (MCK) announced that it has completed the acquisition of Canada-based Rexall Health for $2.1 billion